Somnus Therapeutics, Inc. (Bedminster, NJ) is a private drug development company formed by Care Capital LLC. The company is developing an improved therapeutic to address the top need of insomnia patients: preventing mid-night awakenings without next-day hangovers.

Somnus sees significant opportunity within the multi-billion dollar insomnia market for a new treatment that delivers improved satisfaction to patients and an improved risk/reward profile to investors. To those ends, the company has licensed from SkyePharma PLC (LSE: SKP) a new controlled-release formulation of an established non-benzodiazepine hypnotic pharmaceutical (SKP-1041).

By leveraging the development of a chemical entity from the most successful class of current insomnia drugs with

  • technical advances in formulation
  • controlled-release
  • clinical testing,

we believe we can speed development and reduce clinical development costs, thus increasing return on investment.